Japan Methotrexate Market Size, Share, and COVID-19 Impact Analysis, By Indication (Psoriasis, Rheumatoid Arthritis, and Cancer), By Mode (In-house manufacturing and Contract Manufacturing), and Japan Methotrexate Market Insights, Industry Trend, Forecasts to 2035

Japan Methotrexate Market Insights Forecasts To 2035

• The Japan Methotrexate Market Size is Expected To Grow at a CAGR of around 3.7% from 2025 to 2035
• The Japan Methotrexate Market Size is expected to hold a significant share by 2035

According to a research report published by Spherical Insights & Consulting, The Japan Methotrexate Market Size is Growing at a CAGR of 3.7% from 2025 to 2035. The methotrexate market in Japan is driven by a rise in the incidence of autoimmune disorders and several kinds of malignancies. In addition, demand in the market is also increased by the approval of novel formulations and the creation of combination treatments, which serve a variety of patient demands.

Market Overview

Methotrexate is a multipurpose drug used to treat many diseases, such as severe skin disorders, autoimmune diseases, and cancer. When autoimmune is used as a chemotherapeutic agent to treat diseases and for the treatment of cancer, it is classified as a disease-modifying antirheumatic drug (DMARD). A drug called methotrexate has been used for many years to treat different types of cancer. It is considered as a cytotoxic chemotherapeutic agent and is a member of the antimetabolite drug class. The market for methotrexate is mainly expanding because more people are demanding treatment for chronic diseases such as rheumatoid arthritis, cancer, and autoimmune diseases. Methotrexate acts chemically as a folic acid opposition by blocking the dihydrofolate reductase (DHFR) enzyme. To produce tetrahydrofolate, a cofactor required for the synthesis of nucleotides, DNA, and RNA construction blocks. Methotrexate prevents the proliferation of rapidly dividing cells, including cancer cells and active immune cells. Various forms of methotrexate, such as oral pills, subcutaneous injections, intramuscular injections, and intrathecal injections, provide relief on the basis of the seriousness and nature. It is necessary to adapt to its pharmacokinetic change, adjust the dose effectiveness, and reduce toxicity.

Report Coverage

This research report categorizes the market for the Japan methotrexate market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan methotrexate market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan methotrexate market.

Driving Factors

The methotrexate market in Japan is driven by the increased incidence of cancer and the prevalence of autoimmune illnesses like psoriasis, Crohn's disease, and rheumatoid arthritis. Adoption is facilitated by its proven effectiveness, cost, and integration into accepted treatment regimens. The market is also developing as a result of rising demand for immunosuppressive treatments, improving healthcare infrastructure, and greater awareness of early intervention.

Restraining Factors

The methotrexate market in Japan is restrained by potential side effects such as gastrointestinal problems, bone marrow suppression, and liver damage.  Additionally, usage is further restricted by the availability of more recent targeted medicines, strict monitoring requirements, and contraindications in specific patient categories.

Market Segmentation

The Japan methotrexate market share is classified into indication and mode.

• The rheumatoid arthritis segment held a significant market share in 2024 and is anticipated to grow at a substantial CAGR during the forecast period.

The Japan methotrexate market is segmented by indication into psoriasis, rheumatoid arthritis, and cancer. Among these, the rheumatoid arthritis segment held a significant market share in 2024 and is anticipated to grow at a substantial CAGR during the forecast period. This is due to the increasing number of individuals with the illness in both industrialized and emerging nations. Furthermore, methotrexate is categorized as a disease-modifying anti-rheumatic medication (DMARD), meaning that by targeting the underlying autoimmune response and joint degradation, it can slow down the progression of RA.

• The in-house manufacturing segment held the majority market share in 2024 and is anticipated to grow at a substantial CAGR during the forecast period.

The Japan methotrexate market is segmented by mode into in-house manufacturing and contract manufacturing. Among these, the in-house manufacturing segment held the majority market share in 2024 and is anticipated to grow at a substantial CAGR during the forecast period. Large pharmaceutical companies frequently choose to produce APIs in-house in order to preserve supply chain control, guarantee consistent, high-quality, and legal access to essential raw ingredients, preserve intellectual property, and allow for customization.  Furthermore, from preclinical trials to late-stage development, these businesses concentrate on intensive research and development operations that aid in the creation of more sophisticated and effective APIs.

Competitive Analysis

The report offers the appropriate analysis of the key organizations/companies involved within the Japan Methotrexates market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Eisai Co., Ltd
• Nippon Medac Co., Ltd.
• Pfizer Japan Inc.
• Chugai Pharmaceutical Co., Ltd.
• Celltrion Healthcare Japan K.K.
• Chiesi Pharma Japan K.K.
• Daiichi Sankyo Co., Ltd.
• Ceolia Pharma Co., Ltd.
• Others

 Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan methotrexate market based on the below-mentioned segments:

Japan Methotrexate Market, By Indication

• Psoriasis
• Rheumatoid Arthritis
• Cancer

Japan Methotrexate Market, By Mode

• In-House Manufacturing
• Contract Manufacturing